Publications

28.06.2024

Diagnostic delay in Hidradenitis suppurativa investigated using data from social media and from statutory health insurances

The study explores diagnostic and treatment pathways for Hidradenitis Suppurativa (HS) by analyzing social media posts, dermatologist and patient surveys, and health insurance claims in Germany. It reveals significant diagnostic delays and frequent misdiagnoses, often taking years for patients to re...

Patient Conversations Real-World Evidence

Read Publication

18.06.2024

The rise of early highly effective multiple sclerosis treatment in Germany

This study examines the shift from treat-to-target to early highly effective treatment (EHT) approaches in managing multiple sclerosis in Germany. Using pharmacy data from 2020 to 2022, it found an increasing preference for EHT, marked by a rise in high-efficacy medication prescriptions. This trend ...

Real-World Data

Read Publication

24.11.2023

Correlation and differences of patient-reported outcomes vs. Likert-Rating of MS symptoms in a real-world cohort using a digital patient app

Multiple sclerosis (MS) is a chronic autoimmune disease that affects 250,000 people in Germany and can severely impair their daily activities. The BRISA app helps MS patients to monitor their disease by regularly recording symptoms. This study investigates whether simplified versions of traditional,...

Real-World Data

Read Publication

14.09.2023

The Impact of the COVID-19 Pandemic on Prescription Drug Use in Patients with Psoriasis Vulgaris in Germany

This study investigates how the COVID-19 pandemic may have influenced the sales volumes of psoriasis medications in Germany. It involves an analysis of pharmacy data spanning from 2019 to 2021, assessing trends in the sales of first- and second-line biologic treatments. The research seeks to identif...

Real-World Data

Read Publication

01.02.2023

The influence of the COVID-19 pandemic on the prescription of multiple sclerosis medication in Germany

The study used data from 539,400 prescriptions that included at least one multiple sclerosis drug. Real-world prescription data show that throughout the COVID-19 pandemic, the use of MS medications and co-prescribed antidepressants was stable. These insights from real-world data demonstrate the valu...

Real-World Data

Read Publication

Stay informed on new healthcare insights!

We are at the dawn of a new healthcare era.

Publications

Related resources

Stay informed on new healthcare insights!

We are at the dawn of a new healthcare era.